Redefining the IBDs using genome-scale molecular phenotyping.

Abstract

The IBDs, Crohn's disease and ulcerative colitis, are chronic inflammatory conditions ofthe gastrointestinal tract resulting from an aberrant immune response to enteric microbiota ingenetically susceptible individuals. Disease presentation and progression within and across IBDs, especially Crohn's disease, are highly heterogeneous in location, severity of inflammation and other phenotypes. Current clinical classifications fail to accurately predict disease course and response to therapies. Genome-wide association studies have identified >240 loci that confer riskof IBD, but the clinical utility of these findings remains unclear, and mechanisms by which thegenetic variants contribute to disease are largely unknown. In the past 5 years, the profiling ofgenome-wide gene expression, epigenomic features and gut microbiota composition in intestinal tissue and faecal samples has uncovered distinct molecular signatures that define IBD subtypes, including within Crohn's disease and ulcerative colitis. In this Review, we summarize studies in both adult and paediatric patients that have identified different IBD subtypes, which in some cases have been associated with distinct clinical phenotypes. We posit that genome-scale molecular phenotyping in large cohorts holds great promise not only to further our understanding of the diverse molecular causes of IBD but also for improving clinical trial design to develop more personalized disease management and treatment.